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Clindamycin-induced Maculopapular Exanthema with 
Preferential Involvement of Striae Distensae: A Koeb-
ner phenomenon?
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Clindamycin is a lincomycin-derived antibiotic 
useful for the treatment of anaerobic and Gram-posi-
tive aerobic bacterial infections. Cutaneous adverse 
reactions are usually maculopapular exanthemas, al-
though hypersensitivity syndrome, acute generalized 
exanthematous pustulosis, and Stevens-Johnson 
syndrome have also been reported (1).
We report the case of a patient with a maculopap-
ular rash triggered by clindamycin who developed 
cutaneous lesions on striae distensae (SD).
A 47-year-old woman was referred to our clinic for 
pruritic cutaneous lesions which had started 6 days 
earlier. Her past clinical history included hyperten-
sion, hypothyroidism, hyperuricemia, cholecystecto-
my, caesarean section, and endometriosis-related ab-
dominal surgery, and she was taking levothyroxine, 
allopurinol, imidapril, and omeprazole. The skin rash 
first developed on her neck and back on the 3rd day of 
clindamycin oral treatment (300 mg every 6 hours), 
which was prescribed as antibiotic prophylaxis for a 
tooth implant. General malaise (but not fever) was 
also reported.
Physical examination revealed an erythematous 
maculopapular eruption symmetrically distributed 
on the neck, abdomen, and back (Figure 1, A), with 
isolated lesions involving the proximal upper and 
lower limbs (Figure 1, B). There was a striking vertical 
distribution of skin lesions along the SD on the lateral 
sides of the abdomen (Figure 1, C). No mucosal in-
volvement was found, and laboratory studies showed 
no abnormalities.
Clindamycin withdrawal was followed by prescrip-
tion of a course of oral deflazacort, starting at 30 mg 
daily and tapering down during a 9-day period. On 
the 5th day of treatment, the rash had almost cleared 
with minimal desquamation (Figure 1, D).
Eight weeks after clearance of the skin rash, in-
formed consent was obtained in order to perform an 
Figure 1. (A) Maculopapular confluent exanthema on the back. (B) Isolated erythematous lesions on the anterior aspect of 
the thighs. (C) Vertically disposed eruption along the striae distensae (SD) on the lateral wall of abdomen. (D) Lesions cleared 
5 days after clindamycin withdrawal.
62 ACTA DERMATOVENEROLOGICA CROATICA
allergological evaluation of clindamycin, including 
prick and intradermal (ID) tests on the forearm and 
patch tests on the upper back (2). For patch testing, 
powder of the commercial capsules (Dalacin®) was 
diluted in petrolatum (pet.) and water (aq.), resulting 
in a final 1% clindamycin dilution. Parenteral clinda-
mycin preparations were used in therapeutic concen-
trations for prick tests (150 mg/mL) and dilutions in 
saline of 1/100 and 1/10 for the ID test. Other authors 
have reported that these concentrations do not seem 
to irritate the skin (3-6). Prick and ID tests were as-
sessed after 20 min and 24 hours, respectively. Patch 
tests were removed after the 2nd day, and late reac-
tions were evaluated on day 2 and day 4. Prick and 
ID test results after 20 min were negative. Late results 
of ID tests with clindamycin (1.5 and 15 mg/mL) were 
positive: erythematous infiltrated papules about 7×7 
mm and 18×15 mm were observed at 24 hours and 
lasted until the 8th day. Patch tests with clindamycin 
1% in pet. and 1% in aq. were also positive (+ on day 2 
and day 4). Positive late skin tests suggested delayed-
type non-IgE-mediated allergic clindamycin hyper-
sensitivity. Oral challenge tests are considered to be 
the gold standard to establish or exclude drug hyper-
sensitivity. Due to the positive result of late skin test 
to clindamycin, oral challenge was not performed in 
our patient (3,5).
The Koebner isomorphic phenomenon has been 
described in cutaneous reactions induced by drugs, 
such as antibiotics and chemotherapy. Chronic pres-
sure on the skin is probably involved in the onset of 
skin lesions in hand-foot eruptions induced by tyro-
sine kinase inhibitors (sorafenib and sutinib). Solar 
exposure and cutaneous trauma also seem to play 
a role in the location of papulopustular eruptions 
caused by endothelial growth factor receptor inhibi-
tors (erlotinib) (7). More frequent involvement in trau-
matized skin and surgical scars has been reported in 
the context of linear IgA bullous dermatosis and leu-
kocytoclastic vasculitis triggered by vancomycin and 
cefuroxime (8).
SD are produced by non-penetrating physi-
cal trauma, similar to friction or pressure. Different 
dermatoses can develop along SD skin lesions (like 
plaque psoriasis, pustular psoriasis, lichen planus, 
vitiligo, discoid lupus erythematosus, lupus vasculitis, 
urticarial vasculitis, or chronic graft-versus-host dis-
ease) (9). 
Bevacizumab, etretinate, and corticosteroid-in-
duced ulcers, hyperpigmentation caused by bleomy-
cin, and urticariform lesions triggered by diclofenac 
are examples of different type of drug-induced ab-
normalities involving SD (10).
In summary, we identified clindamycin as the 
cause of the cutaneous reactions that occurred in our 
patient on the basis of the results of the skin tests and 
clinical history. Our findings confirmed a delayed-
type hypersensitivity reaction, possibly involving a T-
cell-mediated immunologic mechanism. Intradermal 
and patch tests were found to be useful in order to 
confirm the diagnosis (4,5). We did not find reports 
in the literature of drug-induced cutaneous erup-
tions along the SD as a manifestation of a Koebner 
phenomenon. Clinical underreporting of this phe-
nomenon could explain the scarce literature on this 
cutaneous adverse reaction.
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